BioMedNewsBreaks

WednesdaySep 16, 2026 3:43 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Developing Next-Gen Cancer Therapies with Dual-Targeting Approach

VERAXA Biotech (NASDAQ: VRXA) is developing an oncology pipeline centered on engineered antibody therapies, with a particular focus on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting “AND-gated” approach intended to activate therapeutic effects preferentially when two tumor-associated targets are present on the same cancer cell, potentially addressing the challenge of on-target, off-tumor toxicity. The company has reported early laboratory data supporting the concept in both TCE and ADC applications, while its lead BiTAC-TCE has advanced into cell-line development and planned IND/CTA-enabling work following regulatory feedback from Germany’s Paul-Ehrlich-Institute. Separately, VERAXA’s VXA-222 bispecific…

Continue Reading

WednesdaySep 16, 2026 3:22 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Targets Greater Scale Following Q1 Growth

Earth Science Tech (OTC: ETST) recently reported Q1 2027 results that management says demonstrate continued progress from its strategy of acquiring and scaling profitable healthcare, pharmaceutical, and telemedicine businesses. For the quarter ended June 30, 2026, revenue rose 3% to $9.0 million, gross profit increased 3.1% to $6.3 million, net income climbed 57% to $715,697, operating cash flow more than doubled to $707,131, and total assets grew 33.3% to $10.4 million compared with Q1 2026. Looking ahead, ETST plans to expand geographically, develop its telehealth and pharmacy fulfillment platforms, improve operating efficiency, and pursue greater institutional investor participation. To view…

Continue Reading

WednesdaySep 16, 2026 11:00 am

BioMedNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 3 MDMA-Assisted Therapy Trial for PTSD

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced plans to initiate a Health Canada-authorized Phase 3 clinical trial in 2027 evaluating MDMA-assisted therapy for post-traumatic stress disorder (“PTSD”). The trial is intended to enroll up to 100 participants across multiple Canadian sites, focusing on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters and healthcare workers. Participants will receive Optimi’s synthetic MDMA HCl during two supervised sessions combining MDMA and psychotherapy, with the primary efficacy endpoint measuring changes in…

Continue Reading

TuesdaySep 15, 2026 12:29 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced its participation in the 3rd Annual ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto, where Co-founder and Executive Co-chairman Anthony Durkacz will present the company’s recent milestones and future growth strategy. Quantum BioPharma recently announced that the U.S. Food and Drug Administration approved its Investigational New Drug application for Lucid-MS, allowing the company to begin Phase 2 trials of its patented, first-in-class multiple sclerosis program in patients with progressive MS. To…

Continue Reading

MondaySep 14, 2026 1:20 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) was featured in a NetworkNewsAudio Audio Press Release titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” highlighting FDA clearance of the company’s Investigational New Drug (“IND”) application for Lucid-MS. According to the company, the approximately 15,000-page IND submission included a comprehensive package of pharmacology, toxicology and manufacturing data, with the clearance allowing Quantum BioPharma to move directly into a randomized, double-blind, placebo-controlled Phase 2 trial evaluating Lucid-MS in people with multiple sclerosis. Lucid-MS is the company’s patented…

Continue Reading

FridaySep 11, 2026 11:31 am

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports First Half 2026 Results, Advances GelrinC(R) Pivotal Trial 

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, reported financial results for the six months ended June 30, 2026 and provided a corporate and clinical update. The company has recruited and treated 43 of 80 patients in its pivotal Phase III GelrinC(R) U.S. trial and now expects to complete enrollment around year-end. Regentis also expanded its U.S. and European clinical networks, advanced preparations for European commercialization and received regulatory approval in Europe for a new solvent-free manufacturing process that increases GelrinC(R) production yield by 400%. For the first half, Regentis reported a net loss of approximately $2.6 million, or $0.44 per share, compared…

Continue Reading

FridaySep 11, 2026 10:21 am

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Signs Nanox.ARC Distribution Agreement for Costa Rica

Nanox (NASDAQ: NNOX) announced a distribution agreement with Costa Rica-based medical equipment distributor SOLME RC, S.A. to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. SOLME will oversee marketing, distribution, installation, training and ongoing technical support in Costa Rica, where it is a registered supplier to the Caja Costarricense de Seguro Social (“CCSS”), the country principal purchaser and provider of hospital services. Commercialization will follow applicable regulatory registration, including an initial six-month proof-of-concept device registration period before full registration, and Costa Rica represents Nanox third Latin American market this year following…

Continue Reading

FridaySep 11, 2026 9:20 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced its placement in a BioMedWire editorial examining the potential of Lucid-MS to address limitations of existing multiple sclerosis (“MS”) treatments. The editorial highlights Quantum BioPharma’s U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed to protect and potentially rebuild the myelin sheath rather than suppress the immune system. According to the publication, the trial would mark the first time a drug based on this mechanism is tested in people…

Continue Reading

ThursdaySep 10, 2026 1:10 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development

VERAXA Biotech (NASDAQ: VRXA) recently appointed antibody therapeutics specialist Dr. Christoph Erkel as its chief scientific officer, taking responsibility for advancing the company’s proprietary BiTAC(R) technology and broader oncology pipeline toward clinical development. The company’s lead BiTAC-TCE program uses a conditionally active, dual-targeting approach designed to selectively activate T cells against cancer cells while potentially limiting effects on healthy tissue. Recent scientific advice from Germany’s Paul-Ehrlich-Institute provided additional clarity around the program’s proposed non-clinical development strategy, while preclinical data presented at the AACR Annual Meeting showed selective activity against cells expressing both target molecules. Beyond BiTAC, VERAXA is developing bispecific antibody-drug…

Continue Reading

ThursdaySep 10, 2026 12:22 pm

BioMedNewsBreaks — Earth Science Tech Inc.’s (ETST) B2B-B2C Healthcare Platform Powers Continued Revenue Growth

Earth Science Tech (OTC: ETST) is positioning itself as a vertically integrated healthcare company through its subsidiaries RxCompoundStore, Mister Meds, and Peaks Curative, combining compounding pharmacy, telemedicine, clinical support, and fulfillment capabilities. Its B2B and B2C business model allows the company to serve independent clinics while also selling customized medications directly to consumers, creating diversified revenue streams across physical and digital healthcare operations. In FY2026, ETST reported revenue of $35.7 million, up from $33.1 million in FY2025 and $11.95 million in FY2024, while also reporting positive operating cash flow and a stronger balance sheet. The company reduced total liabilities from $3.146…

Continue Reading